Alexandre Rob Rees News Today

Podium Presentation Highlights Opportunity to Improve Burn Wound Healing Assessment Spectral MD Holdings, Ltd. (AIM: SMD), an artificial intelligence (AI) company focused on the development of faster

DeepView AI- Burn Platform is Designed to Improve Diagnostic Accuracy, Enhance Patient Outcomes, and Reduce Healthcare Costs Spectral MD Holdings, Ltd. (AIM: SMD) (or the "Company"), an artificial

Spectral MD is an Artificial Intelligence (AI) company focused on predictive medical diagnostics. The Company's FDA Breakthrough Designated DeepView AI Wound Diagnostics platform ("DeepView") uses

Full year revenue and EBITDA in line with guidance Remain focused on post-COVID-19 growth strategy to become a leading global clinical diagnostics company in infectious diseases Regulatory News: Novacyt

Regulatory News: Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company's genesig COVID-19 3G Real-Time PCR test has been approved

Significant progress against post-COVID-19 growth strategy to offset expected decline in COVID-19 sales Regulatory News: Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist

New freeze-dried, direct-to-PCR assays extend the global reach of Novacyt's PCR portfolio with ability to be transported at ambient temperatures Two PROmate lyophilised assays initially launched

Regulatory News: Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces a trading update for the half year ended 30 June 2022 and provides an update

Regulatory News: Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company's PROmate COVID-19 2G Real-Time PCR test has been approved

Regulatory News: Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that, further to the announcement on 2 November 2021, the Company's genesig